Identifying novel pathways at the interface of immunity and metabolism

About Us

Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases. The Company’s mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm.

Landos was established as an incredibly productive research engine, with a current portfolio of two novel targets anchoring libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting multiple indications in the immunology space, including our lead product candidate and clinical stage program NX-13 for ulcerative colitis (UC).

NX-13 targets the NLRX1 pathway, a mitochondrial-associated regulatory NOD-like receptor. NX-13 is orally-active and gut-selective, allowing target engagement within the GI tract.

In August 2022, the Company reported positive top-line results from a NX-13 Phase 1b trial, demonstrating a favorable safety and tolerability profile in UC patients across a range of once-daily doses. Results also indicate promising early signals of clinical improvement as soon as two weeks in patients’ symptoms and four weeks by endoscopy in exploratory endpoints.

We are currently focused on advancing the clinical development of NX-13 in UC. In April 2023, we initiated the NEXUS Phase 2 proof-of-concept trial to evaluate the safety, efficacy and pharmacokinetics in patients with moderate to severe UC. The Company plans to report topline results in the fourth quarter of 2024.

Management Team

Gregory Oakes

President & Chief Executive Officer

Read More about Gregory Oakes

Jenn Creel

Interim Chief Financial Officer

Read More about Jenn Creel

Fabio Cataldi, MD

Executive Vice President & Chief Medical Officer

Read More about Fabio Cataldi, MD

David Pereira, PhD

Vice President, CMC

Read More about David Pereira, PhD

Dawn Louro

Vice President, Clinical Operations

Read More about Dawn Louro

Claudia Lopez

Vice President, Clinical Development

Read More about Claudia Lopez

Amy Place

Vice President, Project Leadership & Site Engagement

Read More about Amy Place

Rebecca Mosig, PhD

Vice President, Corporate Development

Read More about Rebecca Mosig, PhD

Board of Directors

Gregory Oakes

President & Chief Executive Officer

Read More about Gregory Oakes

Chris Garabedian

Chairman | Xontogeny, Perceptive Advisors

Read More about Chris Garabedian

Roger Adsett

Chief Operating Office of Insmed, Inc.

Read More about Roger Adsett

Alka Batycky, PH.D.


Read More about Alka Batycky, PH.D.

Fred Callori

Xontogeny, Perceptive Advisors

Read More about Fred Callori

Tiago Girão

CFO in Residence of Roivant Sciences

Read More about Tiago Girão

Tim M. Mayleben


Read More about Tim M. Mayleben